written on 17.06.2014

Chinese investor puts up €25m to fund US heart failure trial


Belgian biotech firm Cardio3 BioSciences has signed a pair of deals with Chinese company Medisun International that secures €25m from Medisun to fund an FDA-approved US Phase III of C-Cure, Cardio3's cell therapy for heart failure, and sees the…